Arteriovenous Malformation Market Will Grow Will Grow At Highest Pace Owing To Increased Adoption Of Minimal Invasive Techniques

By Author: Ravina Pandya
Total Articles: 28
Comment this article

Arteriovenous malformations (AVMs), also known as arteriovenous anomalies, are abnormal direct connections between arteries and veins without passing through a capillary bed. AVMs can occur in the brain, spine, lungs, liver or other organs in the body. Symptoms of AVMs include headaches, seizures, neurological deficits and hemorrhage depending on location. Treatment of AVMs aims to obliterate the abnormal connecting vessels and includes surgical resection, embolization and stereotactic radiosurgery.
The arteriovenous malformations market is estimated to be valued at USD 3.14 Bn in 2024 and is expected to reach USD 4.99 Bn by 2031, growing at a compound annual growth rate (CAGR) of 6.8% from 2024 to 2031.

Key Takeaways

Key players operating in the Arteriovenous Malformation Market are Stryker Corporation, Medtronic plc, Johnson & Johnson Services, Inc., Terumo Corporation, Balt Extrusion, Penumbra, Inc.

Growing prevalence of neurological disorders globally as well as increasing adoption of minimally invasive procedures for AVM treatment are expected to drive the Arteriovenous Malformation Market ...
... during the forecast period. According to the Brain Aneurysm Foundation, around 30,000 Americans are diagnosed with brain AVMs each year.

Technological advancements in the fields of embolic agents, surgical navigation systems and radiosurgery equipment have enabled the treatment of complex brain AVMs. Companies are focusing on developing advanced liquid embolic agents, detachable coils and navigational systems to facilitate complete occlusion with minimally invasive procedures.

Market Trends
The use of Onyx liquid embolic agent: Onyx liquid embolic agent has emerged as a viable alternative to n-BCA for the treatment of cerebral arteriovenous malformations. It allows for controlled, penetration of draining veins and complete occlusion.
Growing adoption of stereo electroencephalography (SEEG): SEEG enables high-resolution mapping of the brain and precise localization of AVMs. It is gaining acceptance for presurgical planning and functional mapping prior to surgical resection or radiotherapy.

Market Opportunities
Emerging economies in Asia Pacific and Latin America: Growing healthcare infrastructure and improving reimbursement scenario in developing nations will drive the adoption of advanced AVM treatment technologies in the regions.
Development of bioabsorbable liquid embolics: Bioabsorbable liquid embolics that can be safely absorbed post-occlusion can potentially reduce the need for long-term angiographic follow-up. Compaanis are investing in R&D of novel bioabsorbable agents.

Impact of COVID-19 on AV Malformation Market Growth

The COVID-19 pandemic significantly impacted the growth of the arteriovenous malformation (AVM) market globally. During the initial lockdown periods imposed by various governments, most non-emergency medical procedures were postponed to focus on COVID care. This resulted in declined AVM procedures being performed in 2020. The difficulties in patients' transportation and their apprehension to visit hospitals further reduced AVM treatments. However, emergency AVM procedures continued to avoid severe bleeding risks.

With resumption of normal healthcare services in 2021, the AVM market has started recovering gradually. Though the number of procedures is still less than the pre-COVID levels due to the ongoing virus threat. Healthcare facilities are following strict safety protocols which has increased the treatment costs to some extent. At the same time, teleconsultations and remote monitoring of stable AVM patients have helped in continuity of care during the pandemic. Pharmaceutical companies fast-tracked their drug development programs for COVID-19 but did not delay the pipeline products for AVM.

North America Region Accounts for Largest AV Malformation Market Share

The North American region has accounted for the major share of the global AVM market over the past few years. This is attributed to factors like growing aging population susceptible to AVMs, rising healthcare expenditure, availability of advanced treatment options and high adoption rate of new technologies in countries like the US and Canada. According to various estimates, the US market alone represents around 40% of the worldwide AVM procedures performed annually. The region is also hub of key market players and regular new product launches.

Asia Pacific Emerging as the Fastest Growing Region

On the other hand, the Asia Pacific region has emerged as the fastest growing market for AVM treatment globally. This is majorly due to increasing incidence of AVMs, growing medical tourism industry and massive healthcare investments by various governments. Countries like China, India, Japan and South Korea are the driving engines of the APAC AVM market growth. Rising patient awareness, expanding private healthcare infrastructure and gradual inclusion of high-end therapies in national insurance plans will further propel the regional market in the coming years.
Get More Insights On- Arteriovenous Malformation Market
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.
(https://www.linkedin.com/in/ravina-pandya-1a3984191)